Incyte Corp. (INCY) stock
Price, quality score, analyst targets, a 30-day Kronos AI forecast and a Shariah screen for Incyte Corp., updated every trading day.
Health Care · Biotechnology: Commercial Physical & Biological Resarch
Price
$116.87
+0.23% today
Market cap
$23.6B
Overall quality
—
Kronos AI 30-day
−1.2%
3 of 8 simulated paths end higher
Incyte Corp. (INCY) is a Health Care company in Biotechnology: Commercial Physical & Biological Resarch, worth $23.6B. It trades at $116.87, up 0.23% today. 18 analysts' average target of $133.50 implies +14.2% from today's price. Kronos AI's 30-day forecast is −1.2% (3 of 8 simulated paths end higher).
Open the full interactive analysis →Charts, technical signals, DCF fair value and ownership
Analyst price targets
| Average target | $133.50 |
| Low – high | $104.00 – $157.00 |
| Analysts | 18 |
| Upside to average | +14.2% |
Kronos AI 30-day forecast
| Expected close | $115.21 (−1.2%) |
| Likely range | −9.5% … +4.8% |
| As of | 2026-10-27 |
3 of 8 simulated paths end higher.
Quality scores
Not scored: the financial data for this listing is incomplete.
Shariah screen
| Business activity | Passes |
| Debt and cash (AAOIFI 30%) | Not checked for this listing |
Automated screen of business activity and AAOIFI's 30% debt and cash limits. The 5% impermissible-income test is not applied. Check with a scholar before deciding.
Similar companies in Biotechnology: Commercial Physical & Biological Resarch
For information only, not investment advice. Prices updated: 2026-10-29.